Literature DB >> 16413469

Requirement for CDK4 kinase function in breast cancer.

Qunyan Yu1, Ewa Sicinska, Yan Geng, Marie Ahnström, Agnieszka Zagozdzon, Yinxin Kong, Humphrey Gardner, Hiroaki Kiyokawa, Lyndsay N Harris, Olle Stål, Piotr Sicinski.   

Abstract

Cyclin D1 is overexpressed in the majority of human breast cancers. We previously found that mice lacking cyclin D1 are resistant to mammary carcinomas triggered by the ErbB-2 oncogene. In this study, we investigated which function of cyclin D1 is required for ErbB-2-driven mammary oncogenesis. We report that the ability of cyclin D1 to activate cyclin-dependent kinase CDK4 underlies the critical role for cyclin D1 in breast cancer formation. We also found that the continued presence of CDK4-associated kinase activity is required to maintain breast tumorigenesis. We analyzed primary human breast cancers and found high cyclin D1 levels in a subset (approximately 25%) of ErbB-2-overexpressing tumors. We propose that this subset of breast cancer patients might benefit from inhibiting CDK4 kinase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16413469     DOI: 10.1016/j.ccr.2005.12.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  152 in total

1.  Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle.

Authors:  Miriam Zanuy; Antonio Ramos-Montoya; Oscar Villacañas; Nuria Canela; Anibal Miranda; Esther Aguilar; Neus Agell; Oriol Bachs; Jaime Rubio-Martinez; Maria Dolors Pujol; Wai-Nang P Lee; Silvia Marin; Marta Cascante
Journal:  Metabolomics       Date:  2011-07-08       Impact factor: 4.290

2.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Authors:  Patrick J Roberts; John E Bisi; Jay C Strum; Austin J Combest; David B Darr; Jerry E Usary; William C Zamboni; Kwok-Kin Wong; Charles M Perou; Norman E Sharpless
Journal:  J Natl Cancer Inst       Date:  2012-02-01       Impact factor: 13.506

Review 3.  CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

Authors:  A-S Tigan; F Bellutti; K Kollmann; G Tebb; V Sexl
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

Review 4.  The Role of CDK4/6 Inhibition in Breast Cancer.

Authors:  Conleth G Murphy; Maura N Dickler
Journal:  Oncologist       Date:  2015-04-15

5.  Loss of cyclin D1 impairs cerebellar development and suppresses medulloblastoma formation.

Authors:  Jennifer Pogoriler; Kathleen Millen; Manuel Utset; Wei Du
Journal:  Development       Date:  2006-08-30       Impact factor: 6.868

Review 6.  The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.

Authors:  Ami N Shah; Massimo Cristofanilli
Journal:  Curr Treat Options Oncol       Date:  2017-01

Review 7.  Cell cycle, CDKs and cancer: a changing paradigm.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

Review 8.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

Review 9.  Targeting the cell cycle in breast cancer: towards the next phase.

Authors:  K L Thu; I Soria-Bretones; T W Mak; D W Cescon
Journal:  Cell Cycle       Date:  2018-09-11       Impact factor: 4.534

Review 10.  An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.

Authors:  Marie Robert; Jean-Sébastien Frenel; Emmanuelle Bourbouloux; Dominique Berton Rigaud; Anne Patsouris; Paule Augereau; Carole Gourmelon; Mario Campone
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.